SCHEDULE: Octagon Capital Advisors Reports 5.7% Stake in Context Therapeutics

Octagon Capital Advisors LP, along with its affiliates, has disclosed beneficial ownership of 5,250,000 shares, representing 5.7% of Context Therapeutics Inc.'s common stock.

Summary

• Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The filing indicates beneficial ownership of 5,250,000 shares of Context Therapeutics Inc. common stock.
• This ownership stake represents 5.7% of the class of securities.
• Octagon Capital Advisors LP acts as the investment manager for Octagon Investments Master Fund LP.
• Ting Jia is identified as the principal beneficial owner of Octagon Capital Advisors LP and its managing member.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on existing ownership stakes rather than new strategic developments or financial performance.

Positives

• Significant ownership stake of 5.7% by Octagon Capital Advisors LP and its affiliates, indicating substantial investor interest.
• The filing is current as of March 31, 2026, reflecting recent ownership information.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors or individuals who acquire a significant stake in a company but do not intend to control or influence its management. This filing indicates a notable passive investment in Context Therapeutics Inc.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding significant ownership by institutional investors, which can influence market perception and trading activity.

Key Dates

Keywords

Schedule 13G, Context Therapeutics Inc., Octagon Capital Advisors LP, Octagon Investments Master Fund LP, Ting Jia, Beneficial Ownership, Common Stock, SEC Filing